Biogen Says MS Drug Reduces Relapse Rates
Jan 24th 2013 6:01PM
Updated Jan 24th 2013 7:00PM
Biogen Idec announced today that results of a new phase 3 clinical trial show significant reductions in relapse rates for multiple sclerosis patients using peginterferon beta-1a .
In the 1,500-patient study, the injectable drug reduced relapses for 39% of those receiving biweekly doses, and 26% for those receiving monthly doses. In addition, peginterferon beta-1a was also found to decrease the risk of disability progression and reduce the number of new or enlarging brain lesions.
"If approved, peginterferon beta-1a will represent an innovation that offers patients a less frequent dosing schedule of no more than 26 doses annually, as well as a significant reduction in relapses and disability progression," said Gilmore O'Neill, Biogen's vice president of global neurology late-stage clinical development. "Interferons are an important and widely used option for many patients. As a leader in MS, Biogen Idec has the deepest MS pipeline in the industry, and we remain steadfast in our commitment to study compounds that target a broad range of patients' needs."
Peginterferon is a longer-lasting version of Biogen's Avonex, which pulled in $2.7 billion in revenue for FY 2011. As a result of the trial's success, Biogen expects to submit the new drug for U.S. and E.U. regulatory approval this year.
Biogen's stock closed 1.99% up today .
The article Biogen Says MS Drug Reduces Relapse Rates originally appeared on Fool.com.Fool contributor Justin Loiseau has no position in any stocks mentioned. You can follow him on Twitter, @TMFJLo, and on Motley Fool CAPS, @TMFJLo. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.